GSK 223125 Nazare

• Research type

  Research Study

• Full title

  A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Dose Finding, Parallel Group, Phase 2 study of an anti-TSLP Antibody (GSK5784283) in Adults aged 18 to 75 years of age with Uncontrolled Asthma

• IRAS ID

  1011340

• Contact name

  Alina Petris

• Contact email

  alina.m.petris@gsk.com

• Sponsor organisation

  GlaxoSmithKline

• Clinicaltrials.gov Identifier

  NCT06748053

• Research summary

  This is a Phase 2, multicentre, multinational, dose finding, double-blind, randomised, parallel arm, placebo-controlled study to evaluate the effects of 3 dose levels of GSK5784283 in adult participants with uncontrolled asthma. The 52-Week treatment period will consist of 2 phases: an initial dose finding phase (Part A) that will complete once all participants reach Week 26 and an extended dosing phase (Part B,
  Week 26 to 52).

• REC name

  London - South East Research Ethics Committee

• REC reference

  25/LO/0135

• Date of REC Opinion

  10 Jun 2025

• REC opinion

  Further Information Favourable Opinion